PMID- 35736776
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 10
IP  - 3
DP  - 2022 Jun 6
TI  - A Narrative Review of Studies Comparing Efficacy and Safety of Citalopram with 
      Atypical Antipsychotics for Agitation in Behavioral and Psychological Symptoms of 
      Dementia (BPSD).
LID - 10.3390/pharmacy10030061 [doi]
LID - 61
AB  - BACKGROUND: Psychomotor agitation as part of the behavioral and psychological 
      symptoms of dementia (BPSD) is one of the common issues found in aged care 
      facilities. The current inadequate management strategies lead to poor functional 
      and medical outcomes. Psychotropic interventions are the current preferred 
      treatment method, but should these medications be the prescribers' first 
      preference? This review aims to compare pharmacological interventions for 
      psychomotor agitation, judging them according to their effectuality and 
      justifiability profiles. This is to be achieved by retrieving information from 
      Randomized Control Trials (RCTs) and systematic reviews. OBJECTIVES: This review 
      evaluates evidence from RCTs, systematic reviews, and meta-analyses of BPSD 
      patients who have taken agitation treatments. Assessing the efficacy of 
      citalopram, other selective serotonin reuptake inhibitors (SSRIs) and 
      antipsychotic treatments were compared to each other for the purpose of improving 
      agitation outcomes and lowering patient side effects. METHODS: This review 
      includes RCT that compared citalopram with one or more atypical antipsychotics or 
      with a placebo, along with systematic reviews comparing citalopram (SSRI) with 
      antipsychotics such as quetiapine, olanzapine, and risperidone. Studies were 
      extracted by searching and accessing databases, such as PubMed, OVID, and 
      Cochrane with restrictions of date from 2000 to 2021 and published in the English 
      language. CONCLUSION: There are still a limited number of studies including SSRIs 
      for the treatment of agitation in BPSD. SSRIs such as citalopram were associated 
      with a reduction in the symptoms of agitation, and lower risk of adverse effects 
      when compared to antipsychotics. Future studies are required to assess the 
      long-term safety and efficacy of SSRI treatments for agitation in BPSD.
FAU - Qasim, Haider Saddam
AU  - Qasim HS
AD  - Pharmacy Department, School of Medical Sciences and Dentistry, Orange Campus, 
      Charles Sturt University, Orange, NSW 2800, Australia.
FAU - Simpson, Maree Donna
AU  - Simpson MD
AD  - Pharmacy Department, School of Medical Sciences and Dentistry, Orange Campus, 
      Charles Sturt University, Orange, NSW 2800, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220606
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC9228736
OTO - NOTNLM
OT  - BPSD
OT  - SSRIs
OT  - agitation
OT  - antipsychotics
OT  - citalopram
OT  - dementia
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/24 06:00
MHDA- 2022/06/24 06:01
PMCR- 2022/06/06
CRDT- 2022/06/23 10:33
PHST- 2022/03/13 00:00 [received]
PHST- 2022/05/14 00:00 [revised]
PHST- 2022/05/19 00:00 [accepted]
PHST- 2022/06/23 10:33 [entrez]
PHST- 2022/06/24 06:00 [pubmed]
PHST- 2022/06/24 06:01 [medline]
PHST- 2022/06/06 00:00 [pmc-release]
AID - pharmacy10030061 [pii]
AID - pharmacy-10-00061 [pii]
AID - 10.3390/pharmacy10030061 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2022 Jun 6;10(3):61. doi: 10.3390/pharmacy10030061.